Real-World Atopic Dermatitis Patients Often Excluded from Clinical Trials, Study Reveals Safety Differences
核心洞察
Nearly one in four real-world patients with atopic dermatitis (搜索) receiving targeted systemic therapies would not have met eligibility criteria for pivotal randomized clinical trials, primarily due to low baseline disease activity, advanced age, or cardiovascular comorbidities.
Biologic therapies demonstrated comparable safety profiles between trial-eligible and ineligible patients, while JAK inhibitor-treated ineligible patients experienced higher rates of adverse events, particularly acneiform eruption and lipid abnormalities.
The findings highlight significant gaps between highly selected trial populations and diverse real-world patients, supporting the need for more inclusive clinical trial designs and reinforcing the value of real-world evidence in therapeutic decision-making.
A large international study analyzing over 2,000 patients with atopic dermatitis (搜索) has revealed that nearly one-quarter of real-world patients receiving targeted systemic therapies would have been excluded from the pivotal clinical trials that established these treatments' efficacy and safety profiles.
The retrospective analysis, conducted across 16 dermatology centers in seven countries, examined data from 2,154 adolescent and adult patients who initiated treatment with biologic agents (搜索) or oral JAK inhibitors (搜索) between October 2017 and March 2023. Of these patients, 514 (23.9%) were classified as ineligible for clinical trials based on commonly applied inclusion and exclusion criteria.
Primary Exclusion Factors Vary by Treatment Type
The most frequent reason for trial ineligibility was low baseline disease activity, defined as an Eczema Area and Severity Index (EASI) score below 16, affecting 67.9% of ineligible patients. Advanced age (≥75 years) accounted for 21.8% of exclusions, while cardiovascular disease (搜索) represented 13.0% of cases.
Notably, the pattern of ineligibility differed significantly between treatment groups. Among patients receiving JAK inhibitors (搜索), 92.8% of ineligible cases were excluded due to EASI scores below 16, compared to 58.8% in the biologic therapy group. Conversely, patients on biologic therapy were more commonly ineligible due to advanced age (27.7% vs. 5.8%) or cardiovascular disease (搜索) (17.6% vs. 0.7%).
Distinct Patient Profiles Emerge
Trial-ineligible patients presented markedly different demographic and clinical characteristics compared to their eligible counterparts. The ineligible group had a significantly higher median age (51.0 vs. 33.0 years) and demonstrated increased prevalence of non-atopic comorbidities, including hypertension (搜索), diabetes (搜索), and dyslipidemia (搜索).
Paradoxically, classic atopic comorbidities such as asthma (搜索), allergic rhinitis (搜索), and food allergies were less frequent among ineligible patients, suggesting a shift from the traditional "atopic phenotype" to later-onset or comorbidity-driven disease subtypes in older populations.
Baseline disease severity was consistently lower among ineligible patients across all assessed measures, including EASI scores, Dermatology Life Quality Index (DLQI), and pruritus numeric rating scale scores. This likely reflects real-world treatment decisions influenced by quality-of-life impact and comorbidity burden rather than strict disease severity thresholds used in clinical trials.
Safety Profiles Show Treatment-Specific Differences
The analysis revealed distinct safety patterns between biologic and JAK inhibitor therapies when comparing eligible and ineligible patients. Among patients receiving biologic therapies, including dupilumab and tralokinumab, adverse event rates were largely comparable between groups, with 29.8% of eligible and 31.1% of ineligible patients experiencing no adverse events.
However, some differences emerged within the biologic group. Herpetic infections occurred more frequently among ineligible patients (6.4% vs. 3.9%), while non-herpetic infections were reported only in the eligible group (1.2% vs. 0%).
For JAK inhibitor therapy, including abrocitinib, baricitinib, and upadacitinib, ineligible patients showed a trend toward higher overall adverse event rates (52.9% vs. 42.6%). Most notably, acneiform eruption was significantly more common among ineligible patients (18.8% vs. 9.3%), as were lipid abnormalities (19.6% vs. 12.0%).
Clinical Implications for Treatment Selection
The higher frequency of metabolic adverse events among JAK inhibitor-treated ineligible patients may reflect their greater burden of baseline comorbidities, including dyslipidemia (搜索), which could increase susceptibility to known class effects of JAK inhibitors (搜索) on lipid regulation.
Current safety communications advising caution when prescribing systemic JAK inhibitors (搜索) in older patients or individuals with cardiovascular risk factors likely contribute to the preferential use of biologics in these populations, as observed in the study data.
Bridging the Evidence Gap
The findings underscore a persistent disconnect between the highly selected populations enrolled in randomized clinical trials and the heterogeneous patients encountered in routine clinical practice. This gap has been observed across other inflammatory dermatoses, where restrictive eligibility criteria limit the external validity of trial results.
Despite substantial proportions of patients not meeting trial criteria, the overall safety profile of both biologics and JAK inhibitors (搜索) remained favorable in real-world settings. No new or unexpected safety signals emerged among patients with significant comorbidities or advanced age, supporting the feasibility of safely using targeted systemic therapies in broader clinical populations.
The study's authors emphasize that real-world evidence is essential to complement clinical trial findings, particularly for understanding treatment safety among older, comorbid, or polypharmacy populations often underrepresented in controlled studies. These findings support calls for more inclusive trial designs that better reflect the diversity of patients treated in everyday clinical practice.
The research highlights the importance of continued real-world surveillance, particularly for JAK inhibitors (搜索) in comorbid populations, to determine whether observed differences in adverse event rates translate into clinically meaningful long-term outcomes, especially regarding cardiovascular risk.